Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Reducing Volume Losses During Fill and Finish

Published: Thursday, October 24, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
Company will be presenting a poster at The Universe of Pre-Filled Syringes and Injection Devices PDA conference in Basel.

The loss of drug product during the filtration and fill process presents a major challenge to pharmaceutical and biologics manufacturers worldwide.

For Cobra Biologics, limiting the loss of customers’ valuable product is paramount.

To better accommodate high value, small volume filling, for example with antibody and plasmid APIs, a project was initiated to modify the fill process with the aim of minimizing product losses.

Careful mapping of the fill process followed by changes in the working procedures and the choice of disposable fluid flow paths, resulted in a more than 10-fold decrease in product waste.

Successful improvement of the process, based on a commercially available system, ensures that a maximum product yield is available for filling and lyophilization, a factor especially important for small batches of high value drug product.

Cobra will be presenting a poster documenting the findings of this project entitled “Minimizing Drug Product Losses in Small Volume Aseptic Filling” at The Universe of Pre-Filled Syringes and Injection Devices PDA conference in Basel, 5-6 November 2013.

Having optimized the filtration process with an impressive reduction in downstream losses to less than 0.1 litre, Cobra’s on-going project will be to further minimize volume losses, enhancing customer product yields, by thorough review of product sampling and validation procedures.

Cobra’s Fill Finish facility was acquired from UniTech Pharma at the end of 2011 and expands an already comprehensive service offering to include sterile drug product production and freeze drying / lyophilization for a wide range of batch sizes from 1 to 200 litres.

Utilizing fully disposable systems affords Cobra increased flexibility for pre-clinical, clinical and commercial manufacture, and customers’ products can be filled in either single-use syringes (0.5 ml - 3ml) or injected vials (0.5ml - 100ml) while meeting rigorous sterility requirements in accordance with aseptic manufacturing procedures.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cobra Biologics Appointed by University of Sheffield
Manufacturing service will scale production of growth hormone developed using ‘ProFuse’ Technology.
Tuesday, November 24, 2015
Cobra Biologics, The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and The University of Manchester Announce Collaboration
Agreement brings together academic and industrial expertise for the scaled manufacture of therapeutic proteins.
Friday, September 25, 2015
Cobra Biologics and Tecrea Awarded £112K Innovate UK Grant to Develop AAV Scalable Production Bioprocess
‘Technology Inspired Innovation’ award to evaluate robust, large scale viral vector production.
Thursday, April 02, 2015
Cobra Biologics & The University of Manchester Receive £217K Innovate UK/BBSRC Funding
Awarded as part of £20M competition bringing innovative biotechnology projects to market.
Monday, February 23, 2015
Cobra Biologics Appoints CSO
Company announces the appointment of Dr Daniel C. Smith as its Chief Scientific Officer.
Wednesday, May 07, 2014
Cobra Biologics, BioCancell Agreement for Promising Cancer Therapy Drug
The Companies have announced the agreement to manufacture BioCancell’s BC-821 cancer drug for clinical trials.
Monday, March 03, 2014
GMP Certification Boost for Cobra Biologics
Extended certification to include QC testing of registered products.
Wednesday, February 12, 2014
Cobra Biologics and Novolytics Develop Bacteriophages Against Infection
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.
Wednesday, June 12, 2013
Cobra Biologics and Recopharma Enter Agreement
Agreement to utilize Cobra’s cell line development service- MaxXpress.
Wednesday, May 29, 2013
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Companies announce agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies.
Tuesday, May 14, 2013
Scientific News
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos